By Professor Jason Grebely

Other

Dore GJ; Grebely J, 2017, Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030, Elsevier, , http://dx.doi.org/10.1016/j.jhep.2017.03.035

Grebely J; Swan T; Hickman M; Bruneau J; Bruggmann P; Dalgard O; Litwin A; Backmund M; Dore GJ, 2017, Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C, Elsevier, , http://dx.doi.org/10.1016/j.jhep.2016.12.028

Back to profile page